Global generic drug and specialty pharmaceuticals maker Mylan has turned to a trio of firms for counsel on its $1.6 billion cash acquisition of Indian generic injectable drug manufacturer Agila Specialties from parent Strides Arcolab.
Mylan is currently the world’s fourth-largest producer of prescription generic drugs. The suburban Pittsburgh-based company states in a press release announcing the deal that purchasing Agila will help it increase its offerings of injectable drugs and expand into emerging markets such as Brazil and India.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
